Brief: Dr Reddy's Launches Oral Semaglutide Biosimilar Obeda In India
20/05/2026 12:24
May 20 (Reuters) - Dr Reddy's Laboratories Ltd REDY.NS: ANNOUNCES LAUNCH OF ORAL SEMAGLUTIDE BIOSIMILAR OBEDA IN INDIA OBEDA PRICED AT 99, 135, AND 225 RUPEES PER TABLET FOR 3 MG, 7 MG,14 MG DOSES, RESPECTIVELY Source text: [ID:] Further company coverage: REDY.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dr Reddys Laboratories
See all newsFocus: US progesterone supplies tighten as menopause treatment demand grows
Factbox: Global drugmakers invest billions to boost US presence
Brief: Dr Reddy's Announces First-To-Market Launch Of Bosutinib Tablets 400Mg In The United States
Advisory: Inadvertently published alert on NYSE tagged to multiple companies withdrawn
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry (updated)